Recent Advances in Thyroid Cancer

Current Problems in Surgery

Volumn 45, Issue 3, 2008, Pages 156-250

  Grubbs, Elizabeth G ^a   Rich, Thereasa A ^a   Li, Guojun ^a   Sturgis, Erich M ^a   Younes, Maher N ^a   Myers, Jeffrey N ^a   Edeiken Monroe, Beth ^a   Fornage, Bruno D ^a   Monroe, Douglas P ^a   Staerkel, Gregg A ^a   Williams, Michelle D ^a   Waguespack, Steven G ^a   Hu, Mimi I ^a   Cote, Gilbert ^a   Gagel, Robert F ^a   Cohen, James ^b   Weber, Randal S ^a   Anaya, Daniel A ^a   Holsinger, F Chris ^a   Perrier, Nancy D ^a   Clayman, Gary L ^a   Evans, Douglas B ^a   more..

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; ALPHA INTERFERON; ANGIOPEPTIN; B RAF KINASE; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; CEP 751; CISPLATIN; DACARBAZINE; DOXORUBICIN; FLUOROURACIL; GROWTH FACTOR; IMATINIB; LESTAURTINIB; LEVOTHYROXINE; LIOTHYRONINE; MONOCLONAL ANTIBODY; N (3,3 DIMETHYL 6 INDOLINYL) 2 (4 PYRIDINYLMETHYLAMINO)NICOTINAMIDE; OCTREOTIDE; PROTEIN RET; PROTEIN TYROSINE KINASE INHIBITOR; RECOMBINANT THYROTROPIN; SORAFENIB; STREPTOZOCIN; SUNITINIB; THYROID HORMONE; THYROTROPIN; THYROXINE; UNINDEXED DRUG; VANDETANIB; VINDESINE;

ANOREXIA; ARTICLE; ASPIRATION BIOPSY; AUTOTRANSPLANTATION; BLEEDING; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER MORTALITY; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CARCINOGENESIS; CELL CYCLE REGULATION; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG WITHDRAWAL; ECHOGRAPHY; ENDOSCOPIC SURGERY; FAMILIAL DISEASE; FATIGUE; GENE MUTATION; GENETIC SUSCEPTIBILITY; GENOMIC INSTABILITY; HEART DISEASE; HISTOPATHOLOGY; HORMONE INHIBITION; HUMAN; HYPERTENSION; HYPOTHYROIDISM; IONIZING RADIATION; LARYNGEAL NERVE; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MINIMALLY INVASIVE SURGERY; MOLECULAR MECHANICS; MONITORING; MONOTHERAPY; NAUSEA; NONHUMAN; OSTEOLYSIS; PATIENT POSITIONING; PREVALENCE; RISK FACTOR; SIDE EFFECT; THYROID CANCER; THYROID FOLLICULAR CARCINOMA; THYROID MEDULLARY CARCINOMA; THYROID NODULE; THYROID PAPILLARY CARCINOMA; THYROID SURGERY; THYROIDECTOMY;

HUMANS; THYROID NEOPLASMS;

EID: 40649113134     PISSN: 00113840     EISSN: None     Source Type: Journal    
DOI: 10.1067/j.cpsurg.2007.12.010     Document Type: Article

References (370)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2006. CA Cancer J Clin 56 2 (2006) 106-130
2. Surveillance Epidemiology and End Results (SEER) Program, 2006. www.seer.cancer.gov Accessed October 2006
3. Kebebew E., Ituarte P.H., Siperstein A.E., et al. Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer 88 5 (2000) 1139-1148
4. Jemal A., Clegg L.X., Ward E., et al. Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival. Cancer 101 1 (2004) 3-27
5. Davies L., and Welch H.G. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 295 18 (2006) 2164-2167
6. Mangano J.J. A post-Chernobyl rise in thyroid cancer in Connecticut, USA. Eur J Cancer Prev 5 1 (1996) 75-81
7. Haselkorn T., Bernstein L., Preston-Martin S., et al. Descriptive epidemiology of thyroid cancer in Los Angeles County, 1972-1995. Cancer Causes Control 11 2 (2000) 163-170
8. Burgess J.R., and Tucker P. Incidence trends for papillary thyroid carcinoma and their correlation with thyroid surgery and thyroid fine-needle aspirate cytology. Thyroid 16 1 (2006) 47-53
9. Leenhardt L., Bernier M.O., Boin-Pineau M.H., et al. Advances in diagnostic practices affect thyroid cancer incidence in France. Eur J Endocrinol 150 2 (2004) 133-139
10. Solares C.A., Penalonzo M.A., Xu M., and Orellana E. Occult papillary thyroid carcinoma in postmortem species: prevalence at autopsy. Am J Otolaryngol 26 2 (2005) 87-90
11. Harach H.R., Franssila K.O., and Wasenius V.M. Occult papillary carcinoma of the thyroid. A "normal" finding in Finland. A systematic autopsy study Cancer 56 3 (1985) 531-538
12. Parkin D.M., Bray F., Ferlay J., and Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 55 2 (2005) 74-108
13. Kamangar F., Dores G.M., and Anderson W.F. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24 14 (2006) 2137-2150
14. Pisani P., Parkin D.M., Bray F., and Ferlay J. Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 83 1 (1999) 18-29
15. Bray F., Sankila R., Ferlay J., and Parkin D.M. Estimates of cancer incidence and mortality in Europe in 1995. Eur J Cancer 38 1 (2002) 99-166
16. Parkin D.M., Bray F., Ferlay J., and Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 94 2 (2001) 153-156
17. Pisani P., Bray F., and Parkin D.M. Estimates of the world-wide prevalence of cancer for 25 sites in the adult population. Int J Cancer 97 1 (2002) 72-81
18. Ain K.B. Anaplastic thyroid carcinoma: a therapeutic challenge. Semin Surg Oncol 16 1 (1999) 64-69
19. Ferlay J., Bray F., Pisani P., and Parkin D.M. GLOBOCAN 2000: Cancer Incidence, Mortality and Prevalence Worldwide. http://www-dep.iarc.fr/globocan/globocan.htm Accessed October 2006
20. Colonna M., Grande E., Jonasson J.G., and Eurocare Working G. Variation in relative survival of thyroid cancers in Europe: results from the analysis on 21 countries over the period 1983-1994 (EUROCARE-3 study). Eur J Cancer 42 15 (2006) 2598-2608
21. Little J.B. Radiation carcinogenesis. Carcinogenesis 21 3 (2000) 397-404
22. Ron E., Lubin J.H., Shore R.E., et al. Thyroid cancer after exposure to external radiation: a pooled analysis of seven studies. Radiat Res 141 3 (1995) 259-277
23. Nagataki S., and Nystrom E. Epidemiology and primary prevention of thyroid cancer. Thyroid 12 10 (2002) 889-896
24. Sources and effects of ionizing radiation. United Nations Scientific Committee on the Effects of Atomic Radiation (2000), United Nations Publication, New York
25. Ron E. Ionizing radiation and cancer risk: evidence from epidemiology. Pediatr Radiol 32 4 (2002) 232-237 discussion 242-4
26. Sarne D., and Schneider A.B. External radiation and thyroid neoplasia. Endocrinol Metab Clin North Am 25 1 (1996) 181-195
27. Holm L.E., Dahlqvist I., Israelsson A., and Lundell G. Malignant thyroid tumors after iodine-131 therapy: a retrospective cohort study. N Engl J Med 303 4 (1980) 188-191
28. Holm L.E., Wiklund K.E., Lundell G.E., et al. Thyroid cancer after diagnostic doses of iodine-131: a retrospective cohort study. J Natl Cancer Inst 80 14 (1988) 1132-1138
29. Ron E. Cancer risks from medical radiation. Health Phys 85 1 (2003) 47-59
30. Kerber R.A., Till J.E., Simon S.L., et al. A cohort study of thyroid disease in relation to fallout from nuclear weapons testing. JAMA 270 17 (1993) 2076-2082
31. Prentice R.L., Kato H., Yoshimoto K., and Mason M. Radiation exposure and thyroid cancer incidence among Hiroshima and Nagasaki residents. Natl Cancer Inst Monogr 62 (1982) 207-212
32. Schlumberger M.J. Papillary and follicular thyroid carcinoma. N Engl J Med 338 5 (1998) 297-306
33. Moysich K.B., Menezes R.J., and Michalek A.M. Chernobyl-related ionising radiation exposure and cancer risk: an epidemiological review. Lancet Oncol 3 5 (2002) 269-279
34. Kopecky K.J., Stepanenko V., Rivkind N., et al. Childhood thyroid cancer, radiation dose from Chernobyl, and dose uncertainties in Bryansk Oblast, Russia: a population-based case-control study. Radiat Res 166 2 (2006) 367-374
35. Tronko M.D., Howe G.R., Bogdanova T.I., et al. A cohort study of thyroid cancer and other thyroid diseases after the Chernobyl accident: thyroid cancer in Ukraine detected during first screening. J Natl Cancer Inst 98 13 (2006) 897-903
36. Cardis E., Kesminiene A., Ivanov V., et al. Risk of thyroid cancer after exposure to 131I in childhood. J Natl Cancer Inst 97 10 (2005) 724-732
37. Ivanov V.K., Gorski A.I., Tsyb A.F., et al. Radiation-epidemiological studies of thyroid cancer incidence among children and adolescents in the Bryansk oblast of Russia after the Chernobyl accident (1991-2001 follow-up period). Radiat Environ Biophys 45 1 (2006) 9-16
38. Negri E., Ron E., Franceschi S., et al. A pooled analysis of case-control studies of thyroid cancer. I. Methods. Cancer Causes Control 10 2 (1999) 131-142
39. Kolonel L.N., Hankin J.H., Wilkens L.R., et al. An epidemiologic study of thyroid cancer in Hawaii. Cancer Causes Control 1 3 (1990) 223-234
40. Franceschi S., Boyle P., Maisonneuve P., et al. The epidemiology of thyroid carcinoma. Crit Rev Oncog 4 1 (1993) 25-52
41. Ron E., Kleinerman R.A., Boice Jr. J.D., et al. A population-based case-control study of thyroid cancer. J Natl Cancer Inst 79 1 (1987) 1-12
42. Franceschi S., Fassina A., Talamini R., et al. Risk factors for thyroid cancer in northern Italy. Int J Epidemiol 18 3 (1989) 578-584
43. Franceschi S., Preston-Martin S., Dal Maso L., et al. A pooled analysis of case-control studies of thyroid cancer. IV. Benign thyroid diseases. Cancer Causes Control 10 6 (1999) 583-595
44. Levi F., Franceschi S., La Vecchia C., et al. Previous thyroid disease and risk of thyroid cancer in Switzerland. Eur J Cancer 27 1 (1991) 85-88
45. Mack W.J., Preston-Martin S., Bernstein L., et al. Reproductive and hormonal risk factors for thyroid cancer in Los Angeles County females. Cancer Epidemiol Biomarkers Prev 8 11 (1999) 991-997
46. McTiernan A.M., Weiss N.S., and Daling J.R. Incidence of thyroid cancer in women in relation to previous exposure to radiation therapy and history of thyroid disease. J Natl Cancer Inst 73 3 (1984) 575-581
47. Preston-Martin S., Jin F., Duda M.J., and Mack W.J. A case-control study of thyroid cancer in women under age 55 in Shanghai (People's Republic of China). Cancer Causes Control 4 5 (1993) 431-440
48. Norton J.A., Doppman J.D., and Jensen R.T. Cancer of the endocrine system. In: DeVita V.T., Hellman S., and Rosenberg S.A. (Eds). Cancer: Principles and Practice of Oncology. 3rd edition (1989), Lippincott, Philadelphia 1314-1344
49. Horn-Ross P.L., Morris J.S., Lee M., et al. Iodine and thyroid cancer risk among women in a multiethnic population: the Bay Area Thyroid Cancer Study. Cancer Epidemiol Biomarkers Prev 10 9 (2001) 979-985
50. Kovacs G.L., Gonda G., Vadasz G., et al. Epidemiology of thyroid microcarcinoma found in autopsy series conducted in areas of different iodine intake. Thyroid 15 2 (2005) 152-157
51. Bosetti C., Negri E., Kolonel L., et al. A pooled analysis of case-control studies of thyroid cancer. VII. Cruciferous and other vegetables (international). Cancer Causes Control 13 8 (2002) 765-775
52. Markaki I., Linos D., and Linos A. The influence of dietary patterns on the development of thyroid cancer. Eur J Cancer 39 13 (2003) 1912-1919
53. Divi R.L., and Doerge D.R. Inhibition of thyroid peroxidase by dietary flavonoids. Chem Res Toxicol 9 1 (1996) 16-23
54. Horn-Ross P.L., Hoggatt K.J., and Lee M.M. Phytoestrogens and thyroid cancer risk: the San Francisco Bay Area thyroid cancer study. Cancer Epidemiol Biomarkers Prev 11 1 (2002) 43-49
55. Haselkorn T., Stewart S.L., and Horn-Ross P.L. Why are thyroid cancer rates so high in Southeast Asian women living in the United States?. The Bay area thyroid cancer study. Cancer Epidemiol Biomarkers Prev 12 2 (2003) 144-150
56. Mack W.J., Preston-Martin S., Bernstein L., and Qian D. Lifestyle and other risk factors for thyroid cancer in Los Angeles County females. Ann Epidemiol 12 6 (2002) 395-401
57. Oh S.W., Yoon Y.S., and Shin S.A. Effects of excess weight on cancer incidences depending on cancer sites and histologic findings among men: Korea National Health Insurance Corporation Study. J Clin Oncol 23 21 (2005) 4742-4754
58. Negri E., Dal Maso L., Ron E., et al. A pooled analysis of case-control studies of thyroid cancer. II. Menstrual and reproductive factors. Cancer Causes Control 10 2 (1999) 143-155
59. La Vecchia C., Ron E., Franceschi S., et al. A pooled analysis of case-control studies of thyroid cancer. III. Oral contraceptives, menopausal replacement therapy and other female hormones. Cancer Causes Control 10 2 (1999) 157-166
60. Navarro Silvera S.A., Miller A.B., and Rohan T.E. Risk factors for thyroid cancer: a prospective cohort study. Int J Cancer 116 3 (2005) 433-438
61. Iribarren C., Haselkorn T., Tekawa I.S., and Friedman G.D. Cohort study of thyroid cancer in a San Francisco Bay area population. Int J Cancer 93 5 (2001) 745-750
62. Akslen L.A., Nilssen S., and Kvale G. Reproductive factors and risk of thyroid cancer. A prospective study of 63,090 women from Norway. Br J Cancer 65 5 (1992) 772-774
63. Correa P., and Chen V.W. Endocrine gland cancer. Cancer 75 1 suppl (1995) 338-352
64. Ericsson U.B., and Lindgarde F. Effects of cigarette smoking on thyroid function and the prevalence of goitre, thyrotoxicosis and autoimmune thyroiditis. J Intern Med 229 1 (1991) 67-71
65. Knudsen N., Bulow I., Laurberg P., et al. Alcohol consumption is associated with reduced prevalence of goitre and solitary thyroid nodules. Clin Endocrinol (Oxf) 55 1 (2001) 41-46
66. Mack W.J., Preston-Martin S., Dal Maso L., et al. A pooled analysis of case-control studies of thyroid cancer: cigarette smoking and consumption of alcohol, coffee, and tea. Cancer Causes Control 14 8 (2003) 773-785
67. Galanti M.R., Hansson L., Lund E., et al. Reproductive history and cigarette smoking as risk factors for thyroid cancer in women: a population-based case-control study. Cancer Epidemiol Biomarkers Prev 5 6 (1996) 425-431
68. Rossing M.A., Cushing K.L., Voigt L.F., et al. Risk of papillary thyroid cancer in women in relation to smoking and alcohol consumption. Epidemiology 11 1 (2000) 49-54
69. Pal T., Vogl F.D., Chappuis P.O., et al. Increased risk for nonmedullary thyroid cancer in the first degree relatives of prevalent cases of nonmedullary thyroid cancer: a hospital-based study. J Clin Endocrinol Metab 86 11 (2001) 5307-5312
70. Hemminki K., Li X., Plna K., et al. The nation-wide Swedish family-cancer database-updated structure and familial rates. Acta Oncol 40 6 (2001) 772-777
71. Hemminki K., Eng C., and Chen B. Familial risks for nonmedullary thyroid cancer. J Clin Endocrinol Metab 90 10 (2005) 5747-5753
72. Nagy R., Sweet K., and Eng C. Highly penetrant hereditary cancer syndromes. Oncogene 23 38 (2004) 6445-6470
73. Lindor N.M., and Greene M.H. The concise handbook of family cancer syndromes. Mayo Familial Cancer Program. J Natl Cancer Inst 90 14 (1998) 1039-1071
74. Komminoth P. The RET proto-oncogene in medullary and papillary thyroid carcinoma. Molecular features, pathophysiology and clinical implications. Virchows Arch 431 1 (1997) 1-9
75. Fernandez R.M., Pecina A., Antinolo G., et al. Analysis of RET polymorphisms and haplotypes in the context of sporadic medullary thyroid carcinoma. Thyroid 16 4 (2006) 411-417
76. Alsanea O., and Clark O.H. Familial thyroid cancer. Curr Opin Oncol 13 1 (2001) 44-51
77. Eng C. PTEN: one gene, many syndromes. Hum Mutat 22 3 (2003) 183-198
78. Pilarski R., and Eng C. Will the real Cowden syndrome please stand up (again)?. Expanding mutational and clinical spectra of the PTEN hamartoma tumour syndrome. J Med Genet 41 5 (2004) 323-326
79. Ishikawa Y., Sugano H., Matsumoto T., et al. Unusual features of thyroid carcinomas in Japanese patients with Werner syndrome and possible genotype-phenotype relations to cell type and race. Cancer 85 6 (1999) 1345-1352
80. Eng C. Familial papillary thyroid cancer-many syndromes, too many genes?. J Clin Endocrinol Metab 85 5 (2000) 1755-1757
81. McKay J.D., Lesueur F., Jonard L., et al. Localization of a susceptibility gene for familial nonmedullary thyroid carcinoma to chromosome 2q21. Am J Hum Genet 69 2 (2001) 440-446
82. Takezaki T., Hirose K., Inoue M., et al. Risk factors of thyroid cancer among women in Tokai, Japan. J Epidemiol 6 3 (1996) 140-147
83. Zheng R., Dahlstrom K.R., Wei Q., and Sturgis E.M. Gamma radiation-induced apoptosis, G2 delay, and the risk of salivary and thyroid carcinomas-a preliminary report. Head Neck 26 7 (2004) 612-618
84. Xiong P., Zheng R., Wang L.E., et al. A pilot case-control study of gamma-radiation sensitivity and risk of papillary thyroid cancer. Thyroid 15 2 (2005) 94-99
85. Sigurdson A.J., Hauptmann M., Alexander B.H., et al. DNA damage among thyroid cancer and multiple cancer cases, controls, and long-lived individuals. Mutat Res 586 2 (2005) 173-188
86. Ho T., Zhao C., Zheng R., et al. Glutathione S-transferase polymorphisms and risk of differentiated thyroid carcinomas: a case-control analysis. Arch Otolaryngol Head Neck Surg 132 7 (2006) 756-761
87. Hernandez A., Cespedes W., Xamena N., et al. Glutathione S-transferase polymorphisms in thyroid cancer patients. Cancer Lett 190 1 (2003) 37-44
88. Sturgis E.M., Zhao C., Zheng R., and Wei Q. Radiation response genotype and risk of differentiated thyroid cancer: a case-control analysis. Laryngoscope 115 6 (2005) 938-945
89. Silva S.N., Gil O.M., Oliveira V.C., et al. Association of polymorphisms in ERCC2 gene with non-familial thyroid cancer risk. Cancer Epidemiol Biomarkers Prev 14 10 (2005) 2407-2412
90. Rogounovitch T.I., Saenko V.A., Ashizawa K., et al. TP53 codon 72 polymorphism in radiation-associated human papillary thyroid cancer. Oncol Rep 15 4 (2006) 949-956
91. Ho T., Li G., Zhao C., et al. RET polymorphisms and haplotypes and risk of differentiated thyroid cancer. Laryngoscope 115 6 (2005) 1035-1041
92. Sherman S.I. Thyroid carcinoma. Lancet 361 9356 (2003) 501-511
93. Fagin J.A. How thyroid tumors start and why it matters: kinase mutants as targets for solid cancer pharmacotherapy. J Endocrinol 183 2 (2004) 249-256
94. Carniti C., Perego C., Mondellini P., et al. PP1 inhibitor induces degradation of RETMEN2A and RETMEN2B oncoproteins through proteosomal targeting. Cancer Res 63 9 (2003) 2234-2243
95. Dahia P.L., Marsh D.J., Zheng Z., et al. Somatic deletions and mutations in the Cowden disease gene, PTEN, in sporadic thyroid tumors. Cancer Res 57 21 (1997) 4710-4713
96. Farid N.R., Shi Y., and Zou M. Molecular basis of thyroid cancer. Endocr Rev 15 2 (1994) 202-232
97. Lemoine N.R., Mayall E.S., Wyllie F.S., et al. High frequency of ras oncogene activation in all stages of human thyroid tumorigenesis. Oncogene 4 2 (1989) 159-164
98. Manenti G., Pilotti S., Re F.C., et al. Selective activation of ras oncogenes in follicular and undifferentiated thyroid carcinomas. Eur J Cancer 30A 7 (1994) 987-993
99. Suchy B., Waldmann V., Klugbauer S., and Rabes H.M. Absence of RAS and p53 mutations in thyroid carcinomas of children after Chernobyl in contrast to adult thyroid tumours. Br J Cancer 77 6 (1998) 952-955
100. McIver B., Grebe S.K., and Eberhardt N.L. The PAX8/PPAR gamma fusion oncogene as a potential therapeutic target in follicular thyroid carcinoma. Curr Drug Targets Immune Endocr Metabol Disord 4 3 (2004) 221-234
101. Nikiforova M.N., Lynch R.A., Biddinger P.W., et al. RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol Metab 88 5 (2003) 2318-2326
102. Kroll T.G., Sarraf P., Pecciarini L., et al. PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma. [corrected]. Science 289 5483 (2000) 1357-1360
103. Nikiforova M.N., Biddinger P.W., Caudill C.M., et al. PAX8-PPARgamma rearrangement in thyroid tumors: RT-PCR and immunohistochemical analyses. Am J Surg Pathol 26 8 (2002) 1016-1023
104. Castro M.R., and Gharib H. Thyroid fine-needle aspiration biopsy: progress, practice, and pitfalls. Endocr Pract 9 2 (2003) 128-136
105. Sobrinho-Simoes M., Preto A., Rocha A.S., et al. Molecular pathology of well-differentiated thyroid carcinomas. Virchows Arch 447 5 (2005) 787-793
106. Kimura T., Van Keymeulen A., Golstein J., et al. Regulation of thyroid cell proliferation by TSH and other factors: a critical evaluation of in vitro models. Endocr Rev 22 5 (2001) 631-656
107. Krohn K., Fuhrer D., Bayer Y., et al. Molecular pathogenesis of euthyroid and toxic multinodular goiter. Endocr Rev 26 4 (2005) 504-524
108. Matsuo K., Friedman E., Gejman P.V., and Fagin J.A. The thyrotropin receptor (TSH-R) is not an oncogene for thyroid tumors: structural studies of the TSH-R and the alpha-subunit of Gs in human thyroid neoplasms. J Clin Endocrinol Metab 76 6 (1993) 1446-1451
109. Spambalg D., Sharifi N., Elisei R., et al. Structural studies of the thyrotropin receptor and Gs alpha in human thyroid cancers: low prevalence of mutations predicts infrequent involvement in malignant transformation. J Clin Endocrinol Metab 81 11 (1996) 3898-3901
110. Kimura E.T., Nikiforova M.N., Zhu Z., et al. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 63 7 (2003) 1454-1457
111. Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer 12 2 (2005) 245-262
112. Ciampi R., Knauf J.A., Kerler R., et al. Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer. J Clin Invest 115 1 (2005) 94-101
113. Knauf J.A., Ma X., Smith E.P., et al. Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. Cancer Res 65 10 (2005) 4238-4245
114. Giordano T.J., Kuick R., Thomas D.G., et al. Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis. Oncogene 24 44 (2005) 6646-6656
115. Xing M., Westra W.H., Tufano R.P., et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 90 12 (2005) 6373-6379
116. Trovisco V., Soares P., Preto A., et al. Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients' age but not with tumour aggressiveness. Virchows Arch 446 6 (2005) 589-595
117. Nikiforova M.N., Kimura E.T., Gandhi M., et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 88 11 (2003) 5399-5404
118. Airaksinen M.S., and Saarma M. The GDNF family: signalling, biological functions and therapeutic value. Nat Rev Neurosci 3 5 (2002) 383-394
119. Carlomagno F., Guida T., Anaganti S., et al. Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors. Oncogene 23 36 (2004) 6056-6063
120. Kodama Y., Asai N., Kawai K., et al. The RET proto-oncogene: a molecular therapeutic target in thyroid cancer. Cancer Sci 96 3 (2005) 143-148
121. Carlomagno F., Vitagliano D., Guida T., et al. The kinase inhibitor PP1 blocks tumorigenesis induced by RET oncogenes. Cancer Res 62 4 (2002) 1077-1082
122. Grieco M., Santoro M., Berlingieri M.T., et al. PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell 60 4 (1990) 557-563
123. Fugazzola L., Pilotti S., Pinchera A., et al. Oncogenic rearrangements of the RET proto-oncogene in papillary thyroid carcinomas from children exposed to the Chernobyl nuclear accident. Cancer Res 55 23 (1995) 5617-5620
124. Viglietto G., Chiappetta G., Martinez-Tello F.J., et al. RET/PTC oncogene activation is an early event in thyroid carcinogenesis. Oncogene 11 6 (1995) 1207-1210
125. Kaplan D.R., Martin-Zanca D., and Parada L.F. Tyrosine phosphorylation and tyrosine kinase activity of the trk proto-oncogene product induced by NGF. Nature 350 6314 (1991) 158-160
126. Miller F.D., and Kaplan D.R. On Trk for retrograde signaling. Neuron 32 5 (2001) 767-770
127. Wajjwalku W., Nakamura S., Hasegawa Y., et al. Low frequency of rearrangements of the ret and trk proto-oncogenes in Japanese thyroid papillary carcinomas. Jpn J Cancer Res 83 7 (1992) 671-675
128. Grose R., and Dickson C. Fibroblast growth factor signaling in tumorigenesis. Cytokine Growth Factor Rev 16 2 (2005) 179-186
129. Boelaert K., Horacek J., Holder R.L., et al. Serum thyrotropin concentration as a novel predictor of malignancy in thyroid nodules investigated by fine-needle aspiration. J Clin Endocrinol Metab 91 11 (2006) 4295-4301
130. St Bernard R., Zheng L., Liu W., et al. Fibroblast growth factor receptors as molecular targets in thyroid carcinoma. Endocrinology 146 3 (2005) 1145-1153
131. Morikawa Y., Ishihara Y., Tohya K., et al. Expression of the fibroblast growth factor receptor-1 in human normal tissues and tumors determined by a new monoclonal antibody. Arch Pathol Lab Med 120 5 (1996) 490-496
132. Onose H., Emoto N., Sugihara H., et al. Overexpression of fibroblast growth factor receptor 3 in a human thyroid carcinoma cell line results in overgrowth of the confluent cultures. Eur J Endocrinol 140 2 (1999) 169-173
133. Trovato M., Villari D., Bartolone L., et al. Expression of the hepatocyte growth factor and c-met in normal thyroid, non-neoplastic, and neoplastic nodules. Thyroid 8 2 (1998) 125-131
134. Belfiore A., Gangemi P., Costantino A., et al. Negative/low expression of the Met/hepatocyte growth factor receptor identifies papillary thyroid carcinomas with high risk of distant metastases. J Clin Endocrinol Metab 82 7 (1997) 2322-2328
135. Ruco L.P., Stoppacciaro A., Ballarini F., et al. Met protein and hepatocyte growth factor (HGF) in papillary carcinoma of the thyroid: evidence for a pathogenetic role in tumourigenesis. J Pathol 194 1 (2001) 4-8
136. Scarpino S., D'Alena F.C., Di Napoli A., et al. Papillary carcinoma of the thyroid: evidence for a role for hepatocyte growth factor (HGF) in promoting tumour angiogenesis. J Pathol 199 2 (2003) 243-250
137. Younes M.N., Yazici Y.D., Kim S., et al. Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with NVP-AEE788 for the treatment of aggressive follicular thyroid cancer. Clin Cancer Res 12 11 Pt 1 (2006) 3425-3434
138. Schiff B.A., McMurphy A.B., Jasser S.A., et al. Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer. Clin Cancer Res 10 24 (2004) 8594-8602
139. Takeyama H., Shioya H., Mori Y., et al. Usefulness of radio-guided surgery using technetium-99m methoxyisobutylisonitrile for primary and secondary hyperparathyroidism. World J Surg 28 6 (2004) 576-582
140. Asmis L.M., Gerber H., Kaempf J., and Studer H. Epidermal growth factor stimulates cell proliferation and inhibits iodide uptake of FRTL-5 cells in vitro. J Endocrinol 145 3 (1995) 513-520
141. Holting T., Siperstein A.E., Clark O.H., and Duh Q.Y. Epidermal growth factor (EGF)- and transforming growth factor alpha-stimulated invasion and growth of follicular thyroid cancer cells can be blocked by antagonism to the EGF receptor and tyrosine kinase in vitro. Eur J Endocrinol 132 2 (1995) 229-235
142. Chen H., Nicol T.L., and Udelsman R. Clinically significant, isolated metastatic disease to the thyroid gland. World J Surg 23 2 (1999) 177-180 discussion 181
143. Bunone G., Vigneri P., Mariani L., et al. Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features. Am J Pathol 155 6 (1999) 1967-1976
144. Lyshchik A., Higashi T., Asato R., et al. Thyroid gland tumor diagnosis at US elastography. Radiology 237 1 (2005) 202-211
145. Yasuoka H., Nakamura Y., Zuo H., et al. VEGF-D expression and lymph vessels play an important role for lymph node metastasis in papillary thyroid carcinoma. Mod Pathol 18 8 (2005) 1127-1133
146. Katoh R., Miyagi E., Kawaoi A., et al. Expression of vascular endothelial growth factor (VEGF) in human thyroid neoplasms. Hum Pathol 30 8 (1999) 891-897
147. Pacini F., Elisei R., Capezzone M., et al. Contralateral papillary thyroid cancer is frequent at completion thyroidectomy with no difference in low- and high-risk patients. Thyroid 11 9 (2001) 877-881
148. Volante M., Croce S., Pecchioni C., and Papotti M. E2F-1 transcription factor is overexpressed in oxyphilic thyroid tumors. Mod Pathol 15 10 (2002) 1038-1043
149. Khoo M.L., Ezzat S., Freeman J.L., and Asa S.L. Cyclin D1 protein expression predicts metastatic behavior in thyroid papillary microcarcinomas but is not associated with gene amplification. J Clin Endocrinol Metab 87 4 (2002) 1810-1813
150. Noguchi S., Yamashita H., Murakami N., et al. Small carcinomas of the thyroid. A long-term follow-up of 867 patients. Arch Surg 131 2 (1996) 187-191
151. Erickson L.A., Yousef O.M., Jin L., et al. p27kip1 expression distinguishes papillary hyperplasia in Graves' disease from papillary thyroid carcinoma. Mod Pathol 13 9 (2000) 1014-1019
152. Tung W.S., Shevlin D.W., Bartsch D., et al. Infrequent CDKN2 mutation in human differentiated thyroid cancers. Mol Carcinog 15 1 (1996) 5-10
153. Khoo M.L., Beasley N.J., Ezzat S., et al. Overexpression of cyclin D1 and underexpression of p27 predict lymph node metastases in papillary thyroid carcinoma. J Clin Endocrinol Metab 87 4 (2002) 1814-1818
154. Ito T., Seyama T., Mizuno T., et al. Unique association of p53 mutations with undifferentiated but not with differentiated carcinomas of the thyroid gland. Cancer Res 52 5 (1992) 1369-1371
155. Frates M.C., Benson C.B., Doubilet P.M., et al. Can color Doppler sonography aid in the prediction of malignancy of thyroid nodules?. J Ultrasound Med 22 2 (2003) 127-131 quiz 132-4
156. Monchik J.M., De Petris G., and De Crea C. Occult papillary carcinoma of the thyroid presenting as a cervical cyst. Surgery 129 4 (2001) 429-432
157. Pardal-de-Oliveira F., and Vieira F. Occult papillary carcinoma of the thyroid gland with extensive osseous metastases-a case report with review of the literature. Pathol Res Pract 195 10 (1999) 711-714 discussion 715-6
158. Attie J.N., Khafif R.A., and Steckler R.M. Elective neck dissection in papillary carcinoma of the thyroid. Am J Surg 122 4 (1971) 464-471
159. Papini E., Guglielmi R., Bianchini A., et al. Risk of malignancy in nonpalpable thyroid nodules: predictive value of ultrasound and color-Doppler features. J Clin Endocrinol Metab 87 5 (2002) 1941-1946
160. Ezzat S., Sarti D.A., Cain D.R., and Braunstein G.D. Thyroid incidentalomas. Prevalence by palpation and ultrasonography. Arch Intern Med 154 16 (1994) 1838-1840
161. Kim E.K., Park C.S., Chung W.Y., et al. New sonographic criteria for recommending fine-needle aspiration biopsy of nonpalpable solid nodules of the thyroid. AJR Am J Roentgenol 178 3 (2002) 687-691
162. Kang H.W., No J.H., Chung J.H., et al. Prevalence, clinical and ultrasonographic characteristics of thyroid incidentalomas. Thyroid 14 1 (2004) 29-33
163. Liebeskind A., Sikora A.G., Komisar A., et al. Rates of malignancy in incidentally discovered thyroid nodules evaluated with sonography and fine-needle aspiration. J Ultrasound Med 24 5 (2005) 629-634
164. Brander A., Viikinkoski P., Tuuhea J., et al. Clinical versus ultrasound examination of the thyroid gland in common clinical practice. J Clin Ultrasound 20 1 (1992) 37-42
165. Jarlov A.E., Hegedus L., Gjorup T., and Hansen J.E. Accuracy of the clinical assessment of thyroid size. Dan Med Bull 38 1 (1991) 87-89
166. Koike E., Noguchi S., Yamashita H., et al. Ultrasonographic characteristics of thyroid nodules: prediction of malignancy. Arch Surg 136 3 (2001) 334-337
167. Watters D.A., Ahuja A.T., Evans R.M., et al. Role of ultrasound in the management of thyroid nodules. Am J Surg 164 6 (1992) 654-657
168. Kerr L. High-resolution thyroid ultrasound: the value of color Doppler. Ultrasound Q 12 1 (1994) 21-44
169. Brkljacic B., Cuk V., Tomic-Brzac H., et al. Ultrasonic evaluation of benign and malignant nodules in echographically multinodular thyroids. J Clin Ultrasound 22 2 (1994) 71-76
170. Kakkos S.K., Scopa C.D., Chalmoukis A.K., et al. Relative risk of cancer in sonographically detected thyroid nodules with calcifications. J Clin Ultrasound 28 7 (2000) 347-352
171. Kouvaraki M.A., Shapiro S.E., Fornage B.D., et al. Role of preoperative ultrasonography in the surgical management of patients with thyroid cancer. Surgery 134 6 (2003) 946-954 discussion 954-5
172. Stulak J.M., Grant C.S., Farley D.R., et al. Value of preoperative ultrasonography in the surgical management of initial and reoperative papillary thyroid cancer. Arch Surg 141 5 (2006) 489-494 discussion 494-6
173. Martin H.E. Biopsy by needle puncture and aspiration. EB. Am Surg 92 (1930) 169-181
174. Stewart F. The diagnosis of tumors by aspiration. Am J Pathol 9 (1933) 801-812
175. Frazell E.L.F.F. Papillary carcinoma of the thyroid: a review of 25 years of experience. Cancer 11 (1958) 895-922
176. Crockford P.M., and Bain G.O. Fine-needle aspiration biopsy of the thyroid. Can Med Assoc J 110 9 (1974) 1029-1032
177. Miller J.M., Hamburger J.I., and Kini S. Diagnosis of thyroid nodules. Use of fine-needle aspiration and needle biopsy. JAMA 241 5 (1979) 481-484
178. Yang G.C., Liebeskind D., and Messina A.V. Ultrasound-guided fine-needle aspiration of the thyroid assessed by Ultrafast Papanicolaou stain: data from 1135 biopsies with a two- to six-year follow-up. Thyroid 11 6 (2001) 581-589
179. Kim S.J., Kim E.K., Park C.S., et al. Ultrasound-guided fine-needle aspiration biopsy in nonpalpable thyroid nodules: is it useful in infracentimetric nodules?. Yonsei Med J 44 4 (2003) 635-640
180. Baloch Z.W., Tam D., Langer J., et al. Ultrasound-guided fine-needle aspiration biopsy of the thyroid: role of on-site assessment and multiple cytologic preparations. Diagn Cytopathol 23 6 (2000) 425-429
181. Yokozawa T., Miyauchi A., Kuma K., and Sugawara M. Accurate and simple method of diagnosing thyroid nodules the modified technique of ultrasound-guided fine needle aspiration biopsy. Thyroid 5 2 (1995) 141-145
182. Binyousef H.M., Alzahrani A.S., Al-Sobhi S.S., et al. Preoperative neck ultrasonographic mapping for persistent/recurrent papillary thyroid cancer. World J Surg 28 11 (2004) 1110-1114
183. Dupuy D.E., Monchik J.M., Decrea C., and Pisharodi L. Radiofrequency ablation of regional recurrence from well-differentiated thyroid malignancy. Surgery 130 6 (2001) 971-977
184. Lewis B.D., Hay I.D., Charboneau J.W., et al. Percutaneous ethanol injection for treatment of cervical lymph node metastases in patients with papillary thyroid carcinoma. AJR Am J Roentgenol 178 3 (2002) 699-704
185. Baloch Z., Carayon P., Conte-Devolx B., et al. Laboratory medicine practice guidelines. Laboratory support for the diagnosis and monitoring of thyroid disease. Thyroid 13 1 (2003) 3-126
186. Clark D.P.F.W. Thyroid Cytopathology (2005), Springer, New York
187. DeMay R. Thyroid. The Art and Science of Cytopathology (1996), ASCP Press, Chicago 704-713
188. Kini S. Adequacy, reporting system, and cytopreparatory technique (1987), Igaku-Shoin, New York
189. Hamburger J.I., and Husain M. Semiquantitative criteria for fine-needle biopsy diagnosis: reduced false-negative diagnoses. Diagn Cytopathol 4 1 (1988) 14-17
190. Goellner J.R., Gharib H., Grant C.S., and Johnson D.A. Fine needle aspiration cytology of the thyroid, 1980 to 1986. Acta Cytol 31 5 (1987) 587-590
191. Nguyen G.K., Ginsberg J., and Crockford P.M. Fine-needle aspiration biopsy cytology of the thyroid. Its value and limitations in the diagnosis and management of solitary thyroid nodules. Pathol Annu 26 Pt 1 (1991) 63-91
192. Guidelines of the Papanicolaou Society of Cytopathology for the Examination of Fine-Needle Aspiration Specimens from Thyroid Nodules. The Papanicolaou Society of Cytopathology Task Force on Standards of Practice. Mod Pathol 9 6 (1996) 710-715
193. Rosai J. Standardized reporting of surgical pathology diagnoses for the major tumor types. A proposal. The Department of Pathology, Memorial Sloan-Kettering Cancer Center. Am J Clin Pathol 100 3 (1993) 240-255
194. In: Greene F.L., Page D.L., Fleming I.D., et al. (Eds). AJCC Cancer Staging Manual. 6th ed. (2002), Springer-Verlag, New York
195. Byar D.P., Green S.B., Dor P., et al. A prognostic index for thyroid carcinoma. A study of the E.O.R.T.C. Thyroid Cancer Cooperative Group. Eur J Cancer 15 8 (1979) 1033-1041
196. Hay I.D., Grant C.S., Taylor W.F., and McConahey W.M. Ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma: a retrospective analysis of surgical outcome using a novel prognostic scoring system. Surgery 102 6 (1987) 1088-1095
197. Cady B., and Rossi R. An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery 104 6 (1988) 947-953
198. Hay I.D., Bergstralh E.J., Goellner J.R., et al. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery 114 6 (1993) 1050-1057 discussion 1057-8
199. Mazzaferri E.L., and Jhiang S.M. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 97 5 (1994) 418-428
200. Shaha A.R., Loree T.R., and Shah J.P. Prognostic factors and risk group analysis in follicular carcinoma of the thyroid. Surgery 118 6 (1995) 1131-1136 discussion 1136-8
201. Sherman S.I., Brierley J.D., Sperling M., et al. Prospective multicenter study of thyroid carcinoma treatment: initial analysis of staging and outcome. National Thyroid Cancer Treatment Cooperative Study Registry Group. Cancer 83 5 (1998) 1012-1021
202. Vassilopoulou-Sellin R., Schultz P.N., and Haynie T.P. Clinical outcome of patients with papillary thyroid carcinoma who have recurrence after initial radioactive iodine therapy. Cancer 78 3 (1996) 493-501
203. Akslen L.A., and LiVolsi V.A. Prognostic significance of histologic grading compared with subclassification of papillary thyroid carcinoma. Cancer 88 8 (2000) 1902-1908
204. DeLellis R.A., and Williams D. Pathology and Genetics of Tumors of the Endocrine Organs (2004), IARCPress, Lyon
205. Heffess C.S., and Thompson L.D. Minimally invasive follicular thyroid carcinoma. Endocr Pathol 12 4 (2001) 417-422
206. Thompson L.D., Wieneke J.A., Paal E., et al. A clinicopathologic study of minimally invasive follicular carcinoma of the thyroid gland with a review of the English literature. Cancer 91 3 (2001) 505-524
207. LiVolsi V.A., and Baloch Z.W. Follicular neoplasms of the thyroid: view, biases, and experiences. Adv Anat Pathol 11 6 (2004) 279-287
208. Hundahl S.A., Fleming I.D., Fremgen A.M., and Menck H.R. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995. [see comments]. Cancer 83 12 (1998) 2638-2648
209. DeGroot L.J., Kaplan E.L., McCormick M., and Straus F.H. Natural history, treatment, and course of papillary thyroid carcinoma. J Clin Endocrinol Metab 71 2 (1990) 414-424
210. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2007. CA Cancer J Clin 57 1 (2007) 43-66
211. Kouvaraki M.A., Lee J.E., Shapiro S.E., et al. Preventable reoperations for persistent and recurrent papillary thyroid carcinoma. Surgery 136 6 (2004) 1183-1191
212. Hay I.D., McConahey W.M., and Goellner J.R. Managing patients with papillary thyroid carcinoma: insights gained from the Mayo Clinic's experience of treating 2,512 consecutive patients during 1940 through 2000. Trans Am Clin Climatol Assoc 113 (2002) 241-260
213. Mazzaferri E.L., and Young R.L. Papillary thyroid carcinoma: a 10 year follow-up report of the impact of therapy in 576 patients. Am J Med 70 3 (1981) 511-518
214. Esnaola N.F., Cantor S.B., Sherman S.I., et al. Optimal treatment strategy in patients with papillary thyroid cancer: a decision analysis. Surgery 130 6 (2001) 921-930
215. Cody III H.S., and Shah J.P. Locally invasive, well-differentiated thyroid cancer. 22 years' experience at Memorial Sloan-Kettering Cancer Center. Am J Surg 142 4 (1981) 480-483
216. Mizuno S., Funahashi H., Sugiura H., et al. Study on extensive lymph node dissection: metastatic lymph nodes in papillary carcinoma of the thyroid. Nippon Geka Gakkai Zasshi 87 8 (1986) 883-888
217. Tisell L.E., Nilsson B., Molne J., et al. Improved survival of patients with papillary thyroid cancer after surgical microdissection. World J Surg 20 7 (1996) 854-859
218. Samaan N.A., Maheshwari Y.K., Nader S., et al. Impact of therapy for differentiated carcinoma of the thyroid: an analysis of 706 cases. J Clin Endocrinol Metab 56 6 (1983) 1131-1138
219. Rossi R.L., Cady B., Silverman M.L., et al. Current results of conservative surgery for differentiated thyroid carcinoma. World J Surg 10 4 (1986) 612-622
220. Cooper D.S., Doherty G.M., Haugen B.R., et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 16 2 (2006) 109-142
221. Grodski S., Cornford L., Sywak M., et al. Routine level VI lymph node dissection for papillary thyroid cancer: surgical technique. ANZ J Surg 77 4 (2007) 203-208
222. Robbins K.T., Clayman G., Levine P.A., et al. Neck dissection classification update: revisions proposed by the American Head and Neck Society and the American Academy of Otolaryngology-Head and Neck Surgery. Arch Otolaryngol Head Neck Surg 128 7 (2002) 751-758
223. Kouvaraki M.A., Shapiro S.E., Lee J.E., et al. Surgical management of thyroid carcinoma. J Natl Compr Canc Netw 3 3 (2005) 458-466
224. Machens A., Hinze R., Thomusch O., and Dralle H. Pattern of nodal metastasis for primary and reoperative thyroid cancer. World J Surg 26 1 (2002) 22-28
225. Qubain S.W., Nakano S., Baba M., et al. Distribution of lymph node micrometastasis in pN0 well-differentiated thyroid carcinoma. Surgery 131 3 (2002) 249-256
226. Machens A., Schneyer U., Holzhausen H.J., et al. Emergence of medullary thyroid carcinoma in a family with the Cys630Arg RET germline mutation. Surgery 136 5 (2004) 1083-1087
227. Musacchio M.J., Kim A.W., Vijungco J.D., and Prinz R.A. Greater local recurrence occurs with "berry picking" than neck dissection in thyroid cancer. Am Surg 69 3 (2003) 191-196 discussion 196-7
228. Morton D.L., and Cochran A.J. The case for lymphatic mapping and sentinel lymphadenectomy in the management of primary melanoma. Br J Dermatol 151 2 (2004) 308-319
229. Dralle H., Damm I., Scheumann G.F., et al. Compartment-oriented microdissection of regional lymph nodes in medullary thyroid carcinoma. Surg Today 24 2 (1994) 112-121
230. Hedayati N., and McHenry C.R. The clinical significance of an isofunctioning thyroid nodule. Am Surg 69 4 (2003) 311-315 discussion 315-6
231. Roh J.L., Park J.Y., and Park C.I. Total thyroidectomy plus neck dissection in differentiated papillary thyroid carcinoma patients: pattern of nodal metastasis, morbidity, recurrence, and postoperative levels of serum parathyroid hormone. Ann Surg 245 4 (2007) 604-610
232. Noguchi S., Noguchi A., and Murakami N. Papillary carcinoma of the thyroid. I. Developing pattern of metastasis. Cancer 26 5 (1970) 1053-1060
233. Noguchi S., and Murakami N. The value of lymph-node dissection in patients with differentiated thyroid cancer. Surg Clin North Am 67 2 (1987) 251-261
234. Noguchi S., Murakami N., Yamashita H., et al. Papillary thyroid carcinoma: modified radical neck dissection improves prognosis. Arch Surg 133 3 (1998) 276-280
235. Thyroid Carcinoma. Clinical Practice Guidelines in Oncology (Version 2.2007) Vol. 2007 (2007), National Comprehensive Cancer Network, Inc. http://www.nccn.org/professionals/physician_gls/PDF/thyroid.pdf Accessed July 2007
236. Dumont J.E., Lamy F., Roger P., and Maenhaut C. Physiological and pathological regulation of thyroid cell proliferation and differentiation by thyrotropin and other factors. Physiol Rev 72 3 (1992) 667-697
237. Arturi F., Scarpelli D., Coco A., et al. Thyrotropin receptor mutations and thyroid hyperfunctioning adenomas ten years after their first discovery: unresolved questions. Thyroid 13 4 (2003) 341-343
238. Cetani F., Tonacchera M., Pinchera A., et al. Genetic analysis of the TSH receptor gene in differentiated human thyroid carcinomas. J Endocrinol Invest 22 4 (1999) 273-278
239. Sheils O.M., and Sweeney E.C. TSH receptor status of thyroid neoplasms-TaqMan RT-PCR analysis of archival material. J Pathol 188 1 (1999) 87-92
240. Pujol P., Daures J.P., Nsakala N., et al. Degree of thyrotropin suppression as a prognostic determinant in differentiated thyroid cancer. J Clin Endocrinol Metab 81 12 (1996) 4318-4323
241. McGriff N.J., Csako G., Gourgiotis L., et al. Effects of thyroid hormone suppression therapy on adverse clinical outcomes in thyroid cancer. Ann Med 34 7-8 (2002) 554-564
242. Jonklaas J., Sarlis N.J., Litofsky D., et al. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid 16 12 (2006) 1229-1242
243. Landau D., Vini L., A'Hern R., and Harmer C. Thyroid cancer in children: the Royal Marsden Hospital experience. Eur J Cancer 36 2 (2000) 214-220
244. Haugen B.R., Pacini F., Reiners C., et al. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab 84 11 (1999) 3877-3885
245. Belfiore A., Russo D., Vigneri R., and Filetti S. Graves' disease, thyroid nodules and thyroid cancer. Clin Endocrinol (Oxf) 55 6 (2001) 711-718
246. Matsuzu K., Segade F., Matsuzu U., et al. Differential expression of glucose transporters in normal and pathologic thyroid tissue. Thyroid 14 10 (2004) 806-812
247. Grozinsky-Glasberg S., Fraser A., Nahshoni E., et al. Thyroxine-triiodothyronine combination therapy versus thyroxine monotherapy for clinical hypothyroidism: meta-analysis of randomized controlled trials. J Clin Endocrinol Metab 91 7 (2006) 2592-2599
248. Burmeister L.A., Goumaz M.O., Mariash C.N., and Oppenheimer J.H. Levothyroxine dose requirements for thyrotropin suppression in the treatment of differentiated thyroid cancer. J Clin Endocrinol Metab 75 2 (1992) 344-350
249. Bogazzi F., Bartalena L., Gasperi M., et al. The various effects of amiodarone on thyroid function. Thyroid 11 5 (2001) 511-519
250. Chen H., Nicol T.L., Zeiger M.A., et al. Hurthle cell neoplasms of the thyroid: are there factors predictive of malignancy?. Ann Surg 227 4 (1998) 542-546
251. Testini M., Rosato L., Avenia N., et al. The impact of single parathyroid gland autotransplantation during thyroid surgery on postoperative hypoparathyroidism: a multicenter study. Transplant Proc 39 1 (2007) 225-230
252. Cooper D.S. Approach to the patient with subclinical hyperthyroidism. J Clin Endocrinol Metab 92 1 (2007) 3-9
253. Eustatia-Rutten C.F., Corssmit E.P., Pereira A.M., et al. Quality of life in longterm exogenous subclinical hyperthyroidism and the effects of restoration of euthyroidism, a randomized controlled trial. Clin Endocrinol (Oxf) 64 3 (2006) 284-291
254. Sun L., Davies T.F., Blair H.C., et al. TSH and bone loss. Ann N Y Acad Sci 1068 (2006) 309-318
255. Karner I., Hrgovic Z., Sijanovic S., et al. Bone mineral density changes and bone turnover in thyroid carcinoma patients treated with supraphysiologic doses of thyroxine. Eur J Med Res 10 11 (2005) 480-488
256. Uzzan B., Campos J., Cucherat M., et al. Effects on bone mass of long term treatment with thyroid hormones: a meta-analysis. J Clin Endocrinol Metab 81 12 (1996) 4278-4289
257. Sawin C.T., Geller A., Wolf P.A., et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med 331 19 (1994) 1249-1252
258. Parle J.V., Maisonneuve P., Sheppard M.C., et al. Prediction of all-cause and cardiovascular mortality in elderly people from one low serum thyrotropin result: a 10-year cohort study. Lancet 358 9285 (2001) 861-865
259. Surks M.I., Ortiz E., Daniels G.H., et al. Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA 291 2 (2004) 228-238
260. DeGroot L.J., and Jameson J.L. Endocrinology. 5th ed. (2006), Elsevier Saunders, Philadelphia
261. Kouvaraki M.A., Shapiro S.E., Perrier N.D., et al. RET proto-oncogene: a review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors. Thyroid 15 6 (2005) 531-544
262. Ponder B.A., Ponder M.A., Coffey R., et al. Risk estimation and screening in families of patients with medullary thyroid carcinoma. Lancet 1 8582 (1988) 397-401
263. Hofstra R.M., Landsvater R.M., Ceccherini I., et al. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature 367 6461 (1994) 375-376
264. Lips C.J., Landsvater R.M., Hoppener J.W., et al. Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia type 2A. N Engl J Med 331 13 (1994) 828-835
265. Brandi M.L., Gagel R.F., Angeli A., et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 86 12 (2001) 5658-5671
266. Yen T.W., Shapiro S.E., Gagel R.F., et al. Medullary thyroid carcinoma: results of a standardized surgical approach in a contemporary series of 80 consecutive patients. Surgery 134 6 (2003) 890-899 discussion 899-901
267. Manie S., Santoro M., Fusco A., and Billaud M. The RET receptor: function in development and dysfunction in congenital malformation. Trends Genet 17 10 (2001) 580-589
268. Schuchardt A., D'Agati V., Larsson-Blomberg L., et al. Defects in the kidney and enteric nervous system of mice lacking the tyrosine kinase receptor Ret. Nature 367 6461 (1994) 380-383
269. Vlahovic G., and Crawford J. Activation of tyrosine kinases in cancer. Oncologist 8 6 (2003) 531-538
270. Pasini B., Hofstra R.M., Yin L., et al. The physical map of the human RET proto-oncogene. Oncogene 11 9 (1995) 1737-1743
271. De Groot J.W., Links T.P., Plukker J.T., et al. RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors. Endocr Rev 27 5 (2006) 535-560
272. Anders J., Kjar S., and Ibanez C.F. Molecular modeling of the extracellular domain of the RET receptor tyrosine kinase reveals multiple cadherin-like domains and a calcium-binding site. J Biol Chem 276 38 (2001) 35808-35817
273. Myers S.M., Eng C., Ponder B.A., and Mulligan L.M. Characterization of RET proto-oncogene 3′ splicing variants and polyadenylation sites: a novel C-terminus for RET. Oncogene 11 10 (1995) 2039-2045
274. Kotzbauer P.T., Lampe P.A., Heuckeroth R.O., et al. Neurturin, a relative of glial-cell-line-derived neurotrophic factor. Nature 384 6608 (1996) 467-470
275. Baloh R.H., Tansey M.G., Lampe P.A., et al. Artemin, a novel member of the GDNF ligand family, supports peripheral and central neurons and signals through the GFRalpha3-RET receptor complex. Neuron 21 6 (1998) 1291-1302
276. Milbrandt J., de Sauvage F.J., Fahrner T.J., et al. Persephin, a novel neurotrophic factor related to GDNF and neurturin. Neuron 20 2 (1998) 245-253
277. Kjaer S., and Ibanez C.F. Identification of a surface for binding to the GDNF-GFR alpha 1 complex in the first cadherin-like domain of RET. J Biol Chem 278 48 (2003) 47898-47904
278. de Groot J.W., Plaza Menacho I., Schepers H., et al. Cellular effects of imatinib on medullary thyroid cancer cells harboring multiple endocrine neoplasia type 2A and 2B associated RET mutations. Surgery 139 6 (2006) 806-814
279. Nunziata V., Giannattasio R., Di Giovanni G., et al. Hereditary localized pruritus in affected members of a kindred with multiple endocrine neoplasia type 2A (Sipple's syndrome). Clin Endocrinol (Oxf) 30 1 (1989) 57-63
280. Bugalho M.J., Domingues R., Santos J.R., et al. Mutation analysis of the RET proto-oncogene and early thyroidectomy: results of a Portuguese cancer centre. Surgery 141 1 (2007) 90-95
281. Gagel R.F., Levy M.L., Donovan D.T., et al. Multiple endocrine neoplasia type 2a associated with cutaneous lichen amyloidosis. Ann Intern Med 111 10 (1989) 802-806
282. Verdy M., Weber A.M., Roy C.C., et al. Hirschsprung's disease in a family with multiple endocrine neoplasia type 2. J Pediatr Gastroenterol Nutr 1 4 (1982) 603-607
283. Arighi E., Borrello M.G., and Sariola H. RET tyrosine kinase signaling in development and cancer. Cytokine Growth Factor Rev 16 4-5 (2005) 441-467
284. Eng C., Smith D.P., Mulligan L.M., et al. Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours. Hum Mol Genet 3 2 (1994) 237-241
285. Gujral T.S., Singh V.K., Jia Z., and Mulligan L.M. Molecular mechanisms of RET receptor-mediated oncogenesis in multiple endocrine neoplasia 2B. Cancer Res 66 22 (2006) 10741-10749
286. Songyang Z., Carraway III K.L., Eck M.J., et al. Catalytic specificity of protein-tyrosine kinases is critical for selective signalling. Nature 373 6514 (1995) 536-539
287. Cranston A.N., Carniti C., Oakhill K., et al. RET is constitutively activated by novel tandem mutations that alter the active site resulting in multiple endocrine neoplasia type 2B. Cancer Res 66 20 (2006) 10179-10187
288. Scherubl H., Raue F., and Ziegler R. Combination chemotherapy of advanced medullary and differentiated thyroid cancer. Phase II study. J Cancer Res Clin Oncol 116 1 (1990) 21-23
289. Schlumberger M., Abdelmoumene N., Delisle M.J., and Couette J.E. Treatment of advanced medullary thyroid cancer with an alternating combination of 5 FU-streptozocin and 5 FU-dacarbazine. The Groupe d'Etude des Tumeurs a Calcitonine (GETC). Br J Cancer 71 2 (1995) 363-365
290. Leboulleux S., Baudin E., Travagli J.P., and Schlumberger M. Medullary thyroid carcinoma. Clin Endocrinol (Oxf) 61 3 (2004) 299-310
291. Grohn P., Kumpulainen E., and Jakobsson M. Response of medullary thyroid cancer to low-dose alpha-interferon therapy. Acta Oncol 29 7 (1990) 950-951
292. Juweid M.E., Hajjar G., Stein R., et al. Initial experience with high-dose radioimmunotherapy of metastatic medullary thyroid cancer using 131I-MN-14 F(ab)2 anti-carcinoembryonic antigen MAb and AHSCR. J Nucl Med 41 1 (2000) 93-103
293. Schott M., Feldkamp J., Klucken M., et al. Calcitonin-specific antitumor immunity in medullary thyroid carcinoma following dendritic cell vaccination. Cancer Immunol Immunother 51 11-12 (2002) 663-668
294. Mahler C., Verhelst J., de Longueville M., and Harris A. Long-term treatment of metastatic medullary thyroid carcinoma with the somatostatin analogue octreotide. Clin Endocrinol (Oxf) 33 2 (1990) 261-269
295. Smid W.M., and Dullaart R.P. Octreotide for medullary thyroid carcinoma associated diarrhoea. Neth J Med 40 5-6 (1992) 240-243
296. Vitale G., Tagliaferri P., Caraglia M., et al. Slow release lanreotide in combination with interferon-alpha2b in the treatment of symptomatic advanced medullary thyroid carcinoma. J Clin Endocrinol Metab 85 3 (2000) 983-988
297. Busse D., Yakes F.M., Lenferink A.E., and Arteaga C.L. Tyrosine kinase inhibitors: rationale, mechanisms of action, and implications for drug resistance. Semin Oncol 28 5 suppl 16 (2001) 47-55
298. Cohen M.S., Hussain H.B., and Moley J.F. Inhibition of medullary thyroid carcinoma cell proliferation and RET phosphorylation by tyrosine kinase inhibitors. Surgery 132 6 (2002) 960-966 discussion 966-7
299. Gross D.J., Munter G., Bitan M., et al. The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R. Endocr Relat Cancer 13 2 (2006) 535-540
300. de Groot J.W., Zonnenberg B.A., Quarles van Ufford-Mannesse P., et al. A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma. J Clin Endocrinol Metab 92 9 (2007) 3466-3469
301. Lanzi C., Cassinelli G., Pensa T., et al. Inhibition of transforming activity of the ret/ptc1 oncoprotein by a 2-indolinone derivative. Int J Cancer 85 3 (2000) 384-390
302. Lanzi C., Cassinelli G., Cuccuru G., et al. Inactivation of Ret/Ptc1 oncoprotein and inhibition of papillary thyroid carcinoma cell proliferation by indolinone RPI-1. Cell Mol Life Sci 60 7 (2003) 1449-1459
303. Cuccuru G., Lanzi C., Cassinelli G., et al. Cellular effects and antitumor activity of RET inhibitor RPI-1 on MEN2A-associated medullary thyroid carcinoma. J Natl Cancer Inst 96 13 (2004) 1006-1014
304. Petrangolini G., Cuccuru G., Lanzi C., et al. Apoptotic cell death induction and angiogenesis inhibition in large established medullary thyroid carcinoma xenografts by Ret inhibitor RPI-1. Biochem Pharmacol 72 4 (2006) 405-414
305. Kim D.W., Jo Y.S., Jung H.S., et al. An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. J Clin Endocrinol Metab 91 10 (2006) 4070-4076
306. Liu Z., Falola J., Zhu X., et al. Antiproliferative effects of Src inhibition on medullary thyroid cancer. J Clin Endocrinol Metab 89 7 (2004) 3503-3509
307. Carlomagno F., Vitagliano D., Guida T., et al. Efficient inhibition of RET/papillary thyroid carcinoma oncogenic kinases by 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2). J Clin Endocrinol Metab 88 4 (2003) 1897-1902
308. Mitsiades C.S., Kotoula V., Poulaki V., et al. Epidermal growth factor receptor as a therapeutic target in human thyroid carcinoma: mutational and functional analysis. J Clin Endocrinol Metab 91 9 (2006) 3662-3666
309. Strock C.J., Park J.I., Rosen M., et al. CEP-701 and CEP-751 inhibit constitutively activated RET tyrosine kinase activity and block medullary thyroid carcinoma cell growth. Cancer Res 63 17 (2003) 5559-5563
310. Carlomagno F., Anaganti S., Guida T., et al. BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst 98 5 (2006) 326-334
311. Carlomagno F., Vitagliano D., Guida T., et al. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res 62 24 (2002) 7284-7290
312. Vidal M., Wells S., Ryan A., and Cagan R. ZD6474 suppresses oncogenic RET isoforms in a Drosophila model for type 2 multiple endocrine neoplasia syndromes and papillary thyroid carcinoma. Cancer Res 65 9 (2005) 3538-3541
313. Wells S.Y.Y., Lakhani V., Hou J., Langmuir P., Headley D., Skinner M., Morse M., Burch W., and Schlumberger M. A phase II trial of ZD6474 in patients with hereditary metastatic medullary thyroid cancer. J Clin Oncol 24 18S (2006) 5533 (Meeting Abstracts)
314. Boughton D., Rosen L., Van Vugt A., Kurzrock R., Eschenberg M., Wiezorek J., Ingram M., Wang D., Stepan D., and Herbst R.S. Safety and antitumor activity of AMG 706 in patients (pts) with thyroid cancer (TC): a subset analysis from a phase 1 dose-finding study. J Clin Oncol 24 18S (2006) 3030 (Meeting Abstracts)
315. Ezzat S., Huang P., Dackiw A., and Asa S.L. Dual inhibition of RET and FGFR4 restrains medullary thyroid cancer cell growth. Clin Cancer Res 11 3 (2005) 1336-1341
316. Strock C.J., Park J.I., Rosen D.M., et al. Activity of irinotecan and the tyrosine kinase inhibitor CEP-751 in medullary thyroid cancer. J Clin Endocrinol Metab 91 1 (2006) 79-84
317. Machens A., Niccoli-Sire P., Hoegel J., et al. Early malignant progression of hereditary medullary thyroid cancer. N Engl J Med 349 16 (2003) 1517-1525
318. Parthasarathy R., Cote G.J., and Gagel R.F. Hammerhead ribozyme-mediated inactivation of mutant RET in medullary thyroid carcinoma. Cancer Res 59 16 (1999) 3911-3914
319. Drosten M., Frilling A., Stiewe T., and Putzer B.M. A new therapeutic approach in medullary thyroid cancer treatment: inhibition of oncogenic RET signaling by adenoviral vector-mediated expression of a dominant-negative RET mutant. Surgery 132 6 (2002) 991-997 discussion 997
320. Yano L., Shimura M., Taniguchi M., et al. Improved gene transfer to neuroblastoma cells by a monoclonal antibody targeting RET, a receptor tyrosine kinase. Hum Gene Ther 11 7 (2000) 995-1004
321. Goetz M.P., Toft D.O., Ames M.M., and Erlichman C. The Hsp90 chaperone complex as a novel target for cancer therapy. Ann Oncol 14 8 (2003) 1169-1176
322. Marsee D.K., Venkateswaran A., Tao H., et al. Inhibition of heat shock protein 90, a novel RET/PTC1-associated protein, increases radioiodide accumulation in thyroid cells. J Biol Chem 279 42 (2004) 43990-43997
323. Cerchia L., Duconge F., Pestourie C., et al. Neutralizing aptamers from whole-cell SELEX inhibit the RET receptor tyrosine kinase. PLoS Biol 3 4 (2005) e123
324. Hennige A.M., Lammers R., Hoppner W., et al. Inhibition of Ret oncogene activity by the protein tyrosine phosphatase SHP1. Endocrinology 142 10 (2001) 4441-4447
325. Zatelli M.C., Piccin D., Tagliati F., et al. SRC homology-2-containing protein tyrosine phosphatase-1 restrains cell proliferation in human medullary thyroid carcinoma. Endocrinology 146 6 (2005) 2692-2698
326. Sanudo J.R., Maranillo E., Leon X., et al. An anatomical study of anastomoses between the laryngeal nerves. Laryngoscope 109 6 (1999) 983-987
327. Sanders I., Wu B.L., Mu L., et al. The innervation of the human larynx. Arch Otolaryngol Head Neck Surg 119 9 (1993) 934-939
328. Nasri S., Beizai P., Ye Y.M., et al. Cross-innervation of the thyroarytenoid muscle by a branch from the external division of the superior laryngeal nerve. Ann Otol Rhinol Laryngol 106 7 Pt 1 (1997) 594-598
329. Petro M.L., Schweinfurth J.M., and Petro A.B. Transcricothyroid, intraoperative monitoring of the vagus nerve. Arch Otolaryngol Head Neck Surg 132 6 (2006) 624-628
330. Marcus B., Edwards B., Yoo S., et al. Recurrent laryngeal nerve monitoring in thyroid and parathyroid surgery: the University of Michigan experience. Laryngoscope 113 2 (2003) 356-361
331. Udelsman R. Experience counts. Ann Surg 240 1 (2004) 26-27
332. Snyder S.K., and Hendricks J.C. Intraoperative neurophysiology testing of the recurrent laryngeal nerve: plaudits and pitfalls. Surgery 138 6 (2005) 1183-1191 discussion 1191-2
333. Witt R.L. Recurrent laryngeal nerve electrophysiologic monitoring in thyroid surgery: the standard of care?. J Voice 19 3 (2005) 497-500
334. Yarbrough D.E., Thompson G.B., Kasperbauer J.L., et al. Intraoperative electromyographic monitoring of the recurrent laryngeal nerve in reoperative thyroid and parathyroid surgery. Surgery 136 6 (2004) 1107-1115
335. Robertson M.L., Steward D.L., Gluckman J.L., and Welge J. Continuous laryngeal nerve integrity monitoring during thyroidectomy: does it reduce risk of injury?. Otolaryngol Head Neck Surg 131 5 (2004) 596-600
336. Hermann M., Hellebart C., and Freissmuth M. Neuromonitoring in thyroid surgery: prospective evaluation of intraoperative electrophysiological responses for the prediction of recurrent laryngeal nerve injury. Ann Surg 240 1 (2004) 9-17
337. Beldi G., Kinsbergen T., and Schlumpf R. Evaluation of intraoperative recurrent nerve monitoring in thyroid surgery. World J Surg 28 6 (2004) 589-591
338. Halsted. Auto and iso-transplantation in dogs of the parathyroid glandules. W. J Exp Med 11 (1908) 175-198
339. Lahey F. The transplantation of parathyroids in partial thyroidectomy. Surg Gynecol Obstet (1926) 508-509
340. Wells Jr. S.A., and Christiansen C. The transplanted parathyroid gland: evaluation of cryopreservation and other environmental factors which affect its function. Surgery 75 1 (1974) 49-55
341. Hickey R.C., and Samaan N.A. Human parathyroid autotransplantation: proved function by radioimmunoassay of plasma parathyroid hormone. Arch Surg 110 8 (1975) 892-895
342. Wingert D.J., Friesen S.R., Iliopoulos J.I., et al. Post-thyroidectomy hypocalcemia. Incidence and risk factors. Am J Surg 152 6 (1986) 606-610
343. Thompson N.W., and Harness J.K. Complications of total thyroidectomy for carcinoma. Surg Gynecol Obstet 131 5 (1970) 861-868
344. Palazzo F.F., Sywak M.S., Sidhu S.B., et al. Parathyroid autotransplantation during total thyroidectomy-does the number of glands transplanted affect outcome?. World J Surg 29 5 (2005) 629-631
345. Abboud B., Sargi Z., Akkam M., and Sleilaty F. Risk factors for postthyroidectomy hypocalcemia. J Am Coll Surg 195 4 (2002) 456-461
346. Kikumori T., Imai T., Tanaka Y., et al. Parathyroid autotransplantation with total thyroidectomy for thyroid carcinoma: long-term follow-up of grafted parathyroid function. Surgery 125 5 (1999) 504-508
347. Tiong H.Y., White S.A., Khanna D.S., et al. An unusual presentation of follicular carcinoma of the thyroid. Thyroid 11 6 (2001) 591-593
348. Lo C.Y., and Lam K.Y. Routine parathyroid autotransplantation during thyroidectomy. Surgery 129 3 (2001) 318-323
349. Huang J., Walker R., Groome P.G., et al. Risk of thyroid carcinoma in a female population after radiotherapy for breast carcinoma. Cancer 92 6 (2001) 1411-1418
350. Thomusch O., Machens A., Sekulla C., et al. The impact of surgical technique on postoperative hypoparathyroidism in bilateral thyroid surgery: a multivariate analysis of 5846 consecutive patients. Surgery 133 2 (2003) 180-185
351. Funahashi H., Satoh Y., Imai T., et al. Our technique of parathyroid autotransplantation in operation for papillary thyroid carcinoma. Surgery 114 1 (1993) 92-96
352. Ohman U., Granberg P.O., and Lindell B. Function of the parathyroid glands after total thyroidectomy. Surg Gynecol Obstet 146 5 (1978) 773-778
353. Shaha A.R., Burnett C., and Jaffe B.M. Parathyroid autotransplantation during thyroid surgery. J Surg Oncol 46 1 (1991) 21-24
354. Cohen M.S., Dilley W.G., Wells Jr. S.A., et al. Long-term functionality of cryopreserved parathyroid autografts: a 13-year prospective analysis. Surgery 138 6 (2005) 1033-1040 discussion 1040-1
355. Caccitolo J.A., Farley D.R., van Heerden J.A., et al. The current role of parathyroid cryopreservation and autotransplantation in parathyroid surgery: an institutional experience. Surgery 122 6 (1997) 1062-1067
356. Brunt L.M., and Sicard G.A. Current status of parathyroid autotransplantation. Semin Surg Oncol 6 2 (1990) 115-121
357. Feldman G.L., Edmonds M.W., Ainsworth P.J., et al. Variable expressivity of familial medullary thyroid carcinoma (FMTC) due to a RET V804M (GTG->ATG) mutation. Surgery 128 1 (2000) 93-98
358. Wagner P.K., Seesko H.G., and Rothmund M. Replantation of cryopreserved human parathyroid tissue. World J Surg 15 6 (1991) 751-755
359. Herrera M.F., Grant C.S., van Heerden J.A., et al. The effect of cryopreservation on cell viability and hormone secretion in human parathyroid tissue. Surgery 112 6 (1992) 1096-1101 discussion 1101-2
360. McHenry C.R., Stenger D.B., and Calandro N.K. The effect of cryopreservation on parathyroid cell viability and function. Am J Surg 174 5 (1997) 481-484
361. Walgenbach S., Rosniatowski R., Bittinger F., et al. Modified cryopreservation and xenotransplantation of human parathyroid tissue. Langenbecks Arch Surg 384 3 (1999) 277-283
362. Ulrich F., Steinmuller T., Rayes N., et al. Cryopreserved human parathyroid tissue: cell cultures for in vitro testing of function. Transplant Proc 33 1-2 (2001) 666-667
363. Bubenicek P., Kobylka P., Povysil C., et al. Viability of parathyroid gland tissue measured by flow cytometry. Cas Lek Cesk 142 10 (2003) 620-624
364. Lombardi C.P., Raffaelli M., Princi P., et al. Video-assisted thyroidectomy: report on the experience of a single center in more than four hundred cases. World J Surg 30 5 (2006) 794-800 discussion 801
365. Miccoli P., Berti P., Materazzi G., et al. Minimally invasive video-assisted thyroidectomy: five years of experience. J Am Coll Surg 199 2 (2004) 243-248
366. Asao T., Kuwano H., Yamaguchi S., et al. Videoscopic thyroidectomy with fine needle-type apparatuses: an approach that does not leave a scar on the neck or anterior chest. Surg Laparosc Endosc Percutan Tech 15 6 (2005) 339-344
367. Lombardi C.P., Raffaelli M., Princi P., et al. Safety of video-assisted thyroidectomy versus conventional surgery. Head Neck 27 1 (2005) 58-64
368. Lombardi C.P.R.M., Princi P., Lulli P., Rossi E.D., Fadda G., and Bellantone R. Minimally invasive video-assisted thyroidectomy for papillary carcinoma: a prospective study of its completeness Vol. 6 (2002), Divisione di Endocrinochirurgia, Istituto di Clinica Chirurgica, Dipartimento di Scienze Chirurgiche, Universita Cattolica del Sacro Cuore, Rome, Italy 1070-1073
369. Skinner M.A., Safford S.D., and Freemerman A.J. RET tyrosine kinase and medullary thyroid cells are unaffected by clinical doses of STI571. Anticancer Res 23 5A (2003) 3601-3606
370. Polverino A., Coxon A., Starnes C., et al. AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. Cancer Res 66 17 (2006) 8715-8721